Quantum-Powered vaccine takes on tough uterine cancer
NCT ID NCT07316361
First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This early-phase trial tests a personalized vaccine made using quantum computing for 40 people with high-risk or returning endometrial cancer. The vaccine is designed to train the immune system to attack each person's unique tumor. The main goals are to check safety and see if the vaccine can be made quickly and trigger an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Biogenea Pharmaceuticals Ltd & Interbalkan Medical Center - International Oncology Center
Thessaloniki, Thessaloniki, 54622, Greece
Conditions
Explore the condition pages connected to this study.